Prospective, Randomized, Double-Blind Trial Investigating the Effect of Doxycycline on Matrix Metalloproteinase Expression Within Atherosclerotic Carotid Plaques
Open Access
- 1 December 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Stroke
- Vol. 33 (12) , 2858-2864
- https://doi.org/10.1161/01.str.0000038098.04291.f6
Abstract
Background and Purpose— Elevated levels of matrix metalloproteinases (MMPs), particularly MMP-1 and MMP-9, have been implicated in plaque rupture. It has been suggested that inhibition of MMPs may stabilize vulnerable atherosclerotic plaques and improve clinical outcome. The aim of the study was to investigate the ability of doxycycline, a nonspecific MMP inhibitor, to reduce MMP concentration in carotid atheroma. Methods— The study design was a prospective, double-blind randomized trial. One hundred patients requiring carotid endarterectomy were randomized to receive 200 mg/d doxycycline or placebo for 2 to 8 weeks before surgery. During endarterectomy, carotid plaques were retrieved. The concentrations of MMPs and doxycycline were determined in the atherosclerotic tissue by enzyme-linked immunosorbent assay and high-performance liquid chromatography, respectively. Clinical events were recorded, as was the rate of preoperative embolization (transcranial Doppler). Results— Analysis of endarterectomized specimens demonstrated a mean doxycycline concentration of 6.0 μg/g wet weight in treated patients. Administration of doxycycline significantly reduced the concentration of MMP-1 in carotid plaques from a mean of 14.8 to 10.3 ng/100g wet weight ( P =0.038). This difference was due to decreased MMP-1 transcript ( P Conclusions— Doxycycline penetrated atherosclerotic plaques with acceptable tissue levels. This resulted in a reduction in MMP-1 concentration because of decreased expression.Keywords
This publication has 28 references indexed in Scilit:
- Matrix metalloproteinases: a tail of a frog that became a princeNature Reviews Molecular Cell Biology, 2002
- Modulation of Matrix Metalloproteinase-1, Its Tissue Inhibitor, and Nuclear Factor-κB by Losartan in Hypercholesterolemic RabbitsJournal of Cardiovascular Pharmacology, 2002
- Antibiotics Effects in a Rabbit Model ofChlamydia pneumoniae–Induced AtherosclerosisThe Journal of Infectious Diseases, 2000
- Rationale and Design of a Secondary Prevention Trial of Antibiotic Use in Patients after Myocardial Infarction: The WIZARD (Weekly Intervention with Zithromax [Azithromycin] for Atherosclerosis and Its Related Disorders) TrialThe Journal of Infectious Diseases, 2000
- Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm diseaseBritish Journal of Surgery, 1999
- Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysisBritish Journal of Surgery, 1999
- Production and Inhibition of the Gelatinolytic Matrix Metalloproteinases in a Human Model of Vein Graft StenosisEuropean Journal of Vascular and Endovascular Surgery, 1999
- Therapeutic Potential of Tetracycline Derivatives to Suppress the Growth of Abdominal Aortic AneurysmsAdvances in Dental Research, 1998
- Inhibition of MMP Synthesis by Doxycycline and Chemically Modified Tetracyclines (CMTs) in Human Endothelial CellsAdvances in Dental Research, 1998
- Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.Journal of Clinical Investigation, 1994